Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC lowered its holdings in Axonics, Inc. (NASDAQ:AXNX - Free Report) by 16.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 80,529 shares of the company's stock after selling 15,572 shares during the period. Oak Ridge Investments LLC owned about 0.16% of Axonics worth $5,605,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of AXNX. AQR Capital Management LLC grew its position in shares of Axonics by 0.9% during the second quarter. AQR Capital Management LLC now owns 18,337 shares of the company's stock worth $1,233,000 after buying an additional 161 shares in the last quarter. Xponance Inc. raised its stake in shares of Axonics by 7.5% in the 2nd quarter. Xponance Inc. now owns 3,231 shares of the company's stock valued at $217,000 after purchasing an additional 225 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Axonics by 31.1% during the first quarter. Headlands Technologies LLC now owns 1,117 shares of the company's stock worth $77,000 after purchasing an additional 265 shares during the last quarter. Arizona State Retirement System grew its stake in Axonics by 2.5% in the second quarter. Arizona State Retirement System now owns 14,278 shares of the company's stock worth $960,000 after purchasing an additional 355 shares in the last quarter. Finally, Whittier Trust Co. increased its holdings in Axonics by 59.1% in the first quarter. Whittier Trust Co. now owns 1,142 shares of the company's stock valued at $79,000 after buying an additional 424 shares during the last quarter. Institutional investors and hedge funds own 99.48% of the company's stock.

Insider Transactions at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now owns 40,362 shares of the company's stock, valued at $2,801,526.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.85% of the company's stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a report on Monday, August 5th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Axonics has an average rating of "Hold" and a consensus target price of $71.00.

Axonics Trading Up 0.1 %

NASDAQ:AXNX traded up $0.07 during mid-day trading on Friday, hitting $70.37. The stock had a trading volume of 506,415 shares, compared to its average volume of 708,096. Axonics, Inc. has a 52 week low of $49.70 and a 52 week high of $70.53. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of -1,759.31 and a beta of 0.82. The company has a 50 day simple moving average of $69.54 and a 200-day simple moving average of $68.30.

Axonics (NASDAQ:AXNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.03. The business had revenue of $114.57 million during the quarter, compared to analyst estimates of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) EPS. As a group, equities research analysts anticipate that Axonics, Inc. will post 0.24 earnings per share for the current year.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.